KMD Bioscience Co., Ltd.
400-621-6806
Service Line：+1-315-239-3085
Address：FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
| Catalog Number | YR1374 |
|---|---|
| Product Name | Anti-Human CD19 Recombinant Antibody(Inebilizumab) |
| Molecular Name | Inebilizumab |
| Alias | Anti-CD19 Recombinant Antibody, Research Grade Inebilizumab |
| CAS Number | 1299440-37-1 |
| Target | CD19[Homo sapiens] |
| Isotype | IgG1 Kappa |
| Clonity | Monoclonal |
| Source | CHO Cells |
| Size | 1mg, 5mg |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Buffer | PBS, pH7.5 |
| Background | Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain. |
| Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Note | This product is for research use only. |
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
Hot Line： +1-315-239-3085
Technical Support：sales@kmdbiosci.com
